Cerus Receives FDA Approval for Use of the INTERCEPT Blood System for Platelets Suspended in 100% Plasma

Go back to Cerus Receives FDA Approval for Use of the INTERCEPT Blood System for Platelets Suspended in 100% Plasma
Cerus Corp (NASDAQ: CERS) Delayed: 2.54 -0.05 (1.93%)
Previous Close $2.59    52 Week High $7.64 
Open $2.56    52 Week Low $4.22 
Day High $2.58    P/E N/A 
Day Low $2.53    EPS $-0.59 
Volume 753,449